Home/ Stocks/ HURA

TuHURA Biosciences, Inc. Common Stock

HURA XNAS

$2.13 +0.02 (+1.18%) ▲ 15-min delayed

Open

$2.15

High

$2.15

Low

$2.08

Volume

66.7K

Market Cap

$134.69M

About TuHURA Biosciences, Inc. Common Stock

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 22 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-7,536,598	$-0.13
FY 2025	$0	$-30,051,977	$-0.63
Q3 2025	$0	$-7,102,455	$-0.14
Q2 2025	$0	$-9,523,835	$-0.21

Related Market News

No specific coverage for HURA yet. Check out our latest market news or earnings calendar.

Get HURA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on TuHURA Biosciences, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.